Insider Insights
21.04.2022
Innovation and affordability of orphan drugs

The paper examines potential reforms to current policies and practices related to orphan drug develo...

Read more
Insider Insights
20.04.2022
Access to cancer drugs

According to the report, the financing of cancer drugs in Spain is “very high” with 90% of oncol...

Read more
Insider Insights
19.04.2022
Payment model to be launched for antibiotics

The UK looks set to become the first country in the world to use a subscription-style payment model ...

Read more
Insider Insights
11.04.2022
Streamline negotiation of price conditions

The amendment includes a number of articles which aims to “streamline the negotiation of the price...

Read more
Insider Insights
25.03.2022
UK-wide commitments for genomics initiatives

According to the Department of Health and Social Care (DHSC), the commitments will enable patients t...

Read more
Insider Insights
24.03.2022
Manufacturer paybacks of E1 billion in relation to

Consequently, paybacks from pharmaceutical manufacturers of around €1 billion will be due from pha...

Read more
News
23.03.2022
PMA Insights: Week 12

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
21.03.2022
Revise payment percentage paid

The DHSC is proposing to increase the statutory scheme payment percentage for 2022 from 10.9% to 14....

Read more
Insider Insights
17.03.2022
Germany: Proposed new pharmaceutical cost

The proposals are set out in the draft Statutory Health Insurance Financial Stabilisation Bill which...

Read more
Articles
10.03.2022
Orphan status higher prices in the UK

Beyond the regulatory level, a well-recognised challenge for companies launching drugs in orphan dis...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.